Mereo Biopharma Group (MREO) Registration Filing summary

Company overview and business model

• Focuses on developing innovative therapeutics for rare diseases, with a portfolio of late-stage clinical product candidates targeting high unmet medical needs.

• Lead assets include setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease, both with multiple regulatory designations.

• Strategy centers on acquiring and developing candidates with substantial prior investment and data from large pharmaceutical companies.

Financial performance and metrics

• As of November 20, 2024, issued share capital was £2,327,184, representing 775,728,034 ordinary shares.

• Financial statements are incorporated by reference from the Annual Report on Form 10-K for the year ended December 31, 2023.

Use of proceeds and capital allocation

• Will not receive any proceeds from the sale of ADSs by selling shareholders; proceeds go directly to the selling shareholders.

• Responsible for registration and related expenses, while selling shareholders bear selling commissions and transfer taxes.